Vor Biopharma Inc. launches an IPO.

IPO of Vor Biopharma Inc. (VOR) will take place on February 4, 2021. Vor Biopharma is a cell-therapy company aimed at treating patients with hematologists malignancies. Using its expertise in hematopoietic stem cell (HSC) biology and genomic engineering, Vor Biopharma genetically modifies HSCs to remove surface targets expressed by cancer cells, and then provides these cells to patients as stem cell transplants. The company is developing its leading candidate product VOR33 and the concomitant therapeutic drug VCAR33 - together they can change the paradigm of hematologic malignancy treatment.

RA Capital Healthcare Fund, 5AM Ventures VI, PureTech Health LLC and FMR are among the company’s current investors.

The listed bokrunners of the IPO are Goldman Sachs, Evercore ISI, Barclays and Stifel.